Optimizing platelet inhibition in clopidogrel poor metabolizers: Therapeutic options and practical considerations

JACC: Cardiovascular Interventions

Volumn 4, Issue 4, 2011, Pages 411-414

  Angiolillo, Dominick J ^a   Ueno, Masafumi ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

antiplatelet therapy; genetics; platelet reactivity

Indexed keywords

CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; TICAGRELOR;

ALLELE; DRUG MEGADOSE; DRUG METABOLISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; NOTE; PRIORITY JOURNAL; THROMBOCYTE;

EID: 79955108369     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2011.03.001     Document Type: Editorial

References (25)

1. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
2. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516 (Pubitemid 46517957)
3. F. Marn, R. Gonzlez-Conejero, P. Capranzano, T.A. Bass, V. Roldn, and D.J. Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy J Am Coll Cardiol 54 2009 1041 1057
4. D.R. Holmes Jr., G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning: " a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association J Am Coll Cardiol 56 2010 321 341
5. J.P. Collet, J.S. Hulot, and G. Anzaha High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2) J Am Coll Cardiol Intv 4 2011 392 402
6. I.S. Kim, Y.H. Jeong, and Y. Park Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype J Am Coll Cardiol Intv 4 2011 381 391
7. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19 (*)2 genotyping J Am Coll Cardiol Intv 4 2011 403 410
8. Y.H. Jeong, I.S. Kim, and Y. Park Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study J Am Coll Cardiol Intv 7 2010 731 741
9. C.M. Barker, S.S. Murray, P.S. Teirstein, D.E. Kandzari, E.J. Topol, and M.J. Price Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity J Am Coll Cardiol Intv 3 2010 1001 1007
10. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716 (Pubitemid 46294761)
11. M.J. Price, P.B. Berger, and P.S. Teirstein Standard versus high-dose clopidogrel based upon platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
12. S. Goto Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding Atheroscler Suppl 6 2005 3 11 (Pubitemid 43263084)
13. D.J. Angiolillo, P. Capranzano, and S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211
14. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 31 2009 1101 1109
15. Y.H. Jeong, J.Y. Hwang, and I.S. Kim Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study Circ Cardiovasc Interv 1 2010 17 26
16. D. Antoniucci No role for triple antiplatelet therapy? J Am Coll Cardiol 57 2011 290 291
17. S.J. Hwang, Y.H. Jeong, and I.S. Kim Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention Circ Cardiovasc Interv 3 2010 450 459
18. D. Vivas, and D.J. Angiolillo Platelet P2Y12 receptor inhibition: an update on clinical drug development Am J Cardiovasc Drugs 10 2010 217 226
19. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
20. A. Pena, J.P. Collet, and J.S. Hulot Can we override clopidogrel resistance? Circulation 119 2009 2854 2857
21. D.J. Angiolillo, J.F. Saucedo, and R. Deraad Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 2010 1017 1023
22. J.L. Ferreiro, D. Sibbing, and D.J. Angiolillo Platelet function testing and risk of bleeding complications Thromb Haemost 103 2010 1128 1135
23. J.L. Mega, T. Simon, and J.P. Collet Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
24. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
25. D.J. Angiolillo Unraveling myths of platelet function and genetic testing: the road to making tailored antiplatelet therapy a reality J Am Coll Cardiol 2011 In press